Hesperos Provides Support for an Investigational Product for a Phase II Clinical Trial with its Human-on-a-Chip®
September 24 2024 - 2:26PM
Business Wire
Hesperos, a leader in recreating human biology for drug
discovery, is pleased to announce its Human-on-a-Chip® technology
played a role in supporting a client’s Investigational New Drug
submission with the Food & Drug Administration for a Phase II
clinical trial of its investigational product DNTH103, highlighting
the contribution of in vitro proof-of-concept data.
Dianthus Therapeutics, Inc. is currently conducting a Phase II
trial of DNTH103, a potent monoclonal antibody that selectively
targets the classical pathway of the complement system, for the
treatment of generalized myasthenia gravis (gMG) [NCT06282159]. gMG
is a chronic autoimmune disorder triggered by the production of
antibodies that interfere with muscle nerve signal transmission and
lead to muscle weakness.
Hesperos’ proprietary neuromuscular junction (NMJ) model
interconnects human cell compartments with devices that monitor
muscle contraction and electrical activity in real-time, providing
physiologically relevant functional readouts. Hesperos researchers
demonstrated that, in the presence of gMG patient serum, DNTH103
can improve nerve cell transmission and thus decrease muscle
fatigue in their preclinical NMJ model.
Dianthus presented these data at the American Academy of
Neurology (AAN) Annual Meeting, which took place April 13-18, 2024
in Denver, Colorado and virtually and at the 10th Congress of the
European Academy of Neurology (EAN), which took place June 29-July
2, 2024 in Helsinki. These presentations can be found in the
Scientific Publications section of the Dianthus website.
“We are pleased that our Human-on-a-Chip® model further
validates the potential role of DNTH103 as a treatment for gMG and
supported Dianthus’ FDA submission for its Phase II gMG clinical
trial,” said Lawrence Florin, CEO, Hesperos, Inc.
Hesperos, Inc.
Hesperos is a global contract research organization (CRO)
specializing in preclinical drug development services through its
Human-on-a-Chip® platform. By replicating key aspects of human
biology (and thus avoiding expensive, time-consuming and often less
informative animal testing), Human-on-a-Chip® platform models
provide product development teams with more meaningful insights
that can accurately predict an agent’s therapeutic profile while
lowering costs and accelerating development timelines.
www.hesperosinc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240924772808/en/
Nathan Post Director of Business Operations
npost@hesperosinc.com